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Opinion
Melatonin is a small indolamine produced in mammals by 
the pineal gland, which regulates the sleep-wake cycle in humans, 
transducing the changes of environmental lightning into a darkness 
production of melatonin. This hormone has several mechanisms 
of action involving receptor-dependent and receptor-independent 
functions. Among these last actions, we can cite melatonin´s ability to 
protect the cells from oxidative stress under ischemia, drug toxicity and 
ionizing radiation [1].
It is well known that melatonin reduces tumor progression in 
animal models undergoing chemically-induced mammary tumors [2]. 
Also in human breast cancer cell lines (in vitro models), melatonin 
shows an oncostatic role on hormone-dependent tumors. Experimental 
evidence suggest that the antiproliferative action of melatonin on 
hormone-dependent breast cancer cells is based on its interaction with 
the synthesis of estrogens or interfering with the estrogen-signaling 
pathways [3,4]. The mechanisms involved in the inhibition of the 
tumoral growth are: i) down-regulation of the circulating levels of 
gonadal estrogens. ii) direct actions at the tumoral cell interfering with 
the activation of the estrogen receptor, therefore behaving as a SERM 
(selective estrogen receptor modulator) and iii) by regulating the 
enzymes involved in the biosynthesis of estrogens in peritumoral tissues 
thus behaving as a SEEM (Selective Estrogen Enzyme Modulator) [5]. 
Moreover, melatonin also exerts an important effect not only over the 
tumoral cells, but also in the tumor microenvironment by decreasing 
the secretion of cytokines by breast cancer cells, which regulates the 
differentiation and the aromatase expression and activity of fibroblasts 
and endothelial cells surrounding malignant cells [6]. Aromatase, 
Steroid sulfotransferase (STS) and 17β-Hydroxysteroid dehydrogenase 
type 1 (17β-HSD1) are key enzymes involved in estradiol formation in 
both normal and breast cancer cells. Therefore, aromatase inhibitors 
are in many cases administered in breast cancer treatment together 
with radiation. As pointed above, melatonin shows an anti-aromatase 
action comparable to that of antiestrogens currently used in breast 
cancer therapy and might be an interesting option to be considered as 
treatment for patients with hormone-dependent tumors.
Since some investigations demonstrated an altered melatonin 
secretion in cancer patients [7], clinical trials have been conducted to 
evaluate the effects of melatonin in human neoplasms. Thus, melatonin 
in combination with chemotherapy did not worsen survival and adverse 
effects of advanced patients with non- small cell lung cancer but there 
was a trend for better health-related quality of life [8,9]. A systematic 
review about the effect of melatonin in conjunction with chemotherapy 
and radiotherapy in cancer patients, which dealt with solid tumors 
concludes that melatonin showed substantial improvements in tumor 
remission, 1-year survival and was able to ameliorate the side effects of 
chemotherapy and radiotherapy [10]. 
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To enhance the radiosensitivity of cancer cells whilst preserving 
as much as possible the health of the non-tumoral cells is one of the 
most important goals in clinical radiology. In patients diagnosed with 
locally advanced, positive estrogen receptor breast cancer, endocrine 
and radiotherapy treatments are commonly applied together. Several 
experimental and clinical studies that have investigated the protective 
effects of melatonin against radiation in vivo have been recently 
published. All of them have focused on the protective actions of the 
pineal hormone against injury in healthy tissues from gamma or X-ray 
when the indolamine is administered prior to exposure to ionizing 
radiation. The main conclusion is that melatonin can counteract, 
acting as a direct free radical scavenger and an indirect antioxidant, 
the production of free radicals induced by radiation. In animal models, 
melatonin shows a great potential to prevent side effects of radiation 
therapy and protects against the damage inflicted to the normal tissue 
[11,12]. Studies carried out in Swiss ND4 mice showed that exposure 
to 950 cGy of whole body radiation caused the death of all the animals 
of the control group 12 days later; however, when mice were pretreated 
with melatonin, almost half of the animals survived at least 30 days 
after treatment [13]. Therefore, if similar results are obtained in human 
patients in clinical trials, the pineal hormone could have a great 
potential to palliate the side effects of radiotherapy in cancer patients.
Apart from the protective effects on normal tissues, it is very 
interesting that antiestrogen treatments had as synergistic effect on 
tumor cells when combined with radiotherapy. Aromatase inhibitors 
such as letrozole, sensitize breast cancer cells to ionizing radiation 
[14]. Recently, fulvestrant, a member of the newest endocrine therapy, 
has also been described as a sensitizing agent to the ionizing effects of 
radiation [15].
As melatonin has both anti-estrogen and anti-aromatase properties 
[4], we have recently investigated its effects on human breast cancer 
cells exposed to radiation. Our group has recently described how 
melatonin, in vitro, acts as a radiosensitizer; we have addressed the 
effects of combining ionizing radiation and melatonin on the hormone-
dependent breast cancer cell line MCF-7. Pretreatment of the cells with 
melatonin one week before radiation resulted in a greater inhibition of 
RAD51 and DNA-protein kinase (PKcs) expression, proteins that are 
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involved in double-strand DNA break repair compared with radiation 
alone. Pretreatment with melatonin also led to a significantly greater 
inhibition of cell proliferation compared with the cells only radiated. 
These results point to a role of melatonin sensitizing breast cancer 
cells to the ionizing effects of radiation, by diminishing the rate of 
proliferation, inducing a cell cycle arrest and causing a downregulation 
of proteins involved in double-strain break repair [16]. Melatonin 
pretreatment results in an enhancement of p53 expression in breast 
cancer cells; this fact might represent a link between melatonin and its 
regulatory effect sensitizing the hormone-dependent breast cancer cells 
to ionizing radiation [17]. Melatonin sensitizes breast cancer cells to the 
ionizing effects of radiation by inducing cell cycle arrest by decreasing 
cell proliferation, downregulating proteins involved in double-strand 
DNA break repair and also by downregulating aromatase. Considering 
that p53 promotes cell cycle arrest, we believe that the modulatory 
action of melatonin through p53 could be the link between the pineal 
hormone and its actions as an enhancer of the radiosensitivity of 
human breast cancer cells.
Moreover, since melatonin shows the ability of modulate the 
expression and activity of the enzymes involved in estrogen synthesis, 
behaving as a selective estrogen enzyme modulator, the effects 
of combining ionizing radiation and melatonin on the enzymes 
necessary for estrogen biosynthesis in hormone-dependent breast 
cancer cells was next evaluated. Melatonin sensitizes the tumor cells 
to radiation by decreasing the activity and expression of proteins 
involved in the synthesis of estrogens, reducing the amount of active 
estrogens at the tumoral cell level. Therefore, in addition to the p53 and 
downregulation of the proteins involved in double-strand DNA repair, 
a second explanation to the enhanced radiosensitivity of cancer cells 
pretreated with melatonin could be the downregulation of aromatase, 
sulfotransferase and 17β-HSD1, which might reduce active estrogen levels.
In summary, we think that melatonin is a molecule with high 
expectations to be considered as an interesting anticancer drug both 
in prevention and treatment of, not only estrogen-dependent tumors, 
but also, other kinds of cancer. The pineal hormone seems to lower the 
damage inflicted to non-tumoral tissues and sensitizes the tumoral cells 
to ionizing radiation; if these promising results can be confirmed in 
human clinical studies, our opinion is that melatonin has the potential 
to be considered as a protective agent in radiation oncology treatments.
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